Evidence map›Paper›PMID 34327473›Full record

ArticleAmerican journal of preventive cardiology2020

The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study.

Ehimen C Aneni, Marcio Sommer Bittencourt, Catherine Teng, Miguel Cainzos-Achirica, Chukwuemeka U Osondu, Ahmed Soliman, Mouaz Al-Mallah, Matthew Buddoff, Edison R Parise, Raul D Santos and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Ehimen C AneniSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Marcio Sommer BittencourtCenter for Clinical and Epidemiological Research, University Hospital and State of São Paulo Cancer Institute (ICESP), University of São Paulo, São Paulo, Brazil.
Catherine TengDepartment of Internal Medicine, Yale New Haven Health - Greenwich Hospital, Greenwich, CT, USA.
Miguel Cainzos-AchiricaHouston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USA.
Chukwuemeka U OsonduBaptist Health South Florida, Miami, FL, USA.
Ahmed SolimanHouston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USA.
Mouaz Al-MallahHouston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USA.
Matthew BuddoffDavid Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Edison R PariseFederal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil.
Raul D SantosHospital Israelita Albert Einstein, São Paulo, Brazil.
Khurram NasirHouston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USA.
Houston Methodist · USUniversidade de São Paulo · BRBaptist Health South Florida · USGreenwich Hospital · USUniversidade Federal de São Paulo · BRUniversity of California, Los Angeles · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies suggest that non-alcoholic fatty liver disease (NAFLD) in lean (BMI<25 ​kg/m

methodsWe analyzed data in our population collected from 2004 to 2016. Medical and demographic history, anthropometric measures, and fasting blood samples were obtained. Participants had ultrasonography to assess for fatty liver. We defined NAFLD as fatty liver in individuals scoring below 8 on the alcohol use disorders identification test (AUDIT). We included data from 9137 individuals who had complete data at baseline and at follow-up.

resultsThe prevalence of lean NAFLD in our cohort was 3.8%. Over the median follow-up period of 2.4 years (range 0.5-9.9 years), lean individuals had 74% (HR: 1.74 (1.39-2.18)) and 67% (1.67 (1.29-2.15)) greater risk of developing elevated BP and elevated glucose, and nearly 3 times the risk of atherogenic dyslipidemia (HR: 2.98 (2.10-4.24)) compared to lean individuals without NAFLD. Lean NAFLD individuals also had higher risk of developing elevated glucose (HR: 1.37 (1.07-1.75)) and atherogenic dyslipidemia (1.46 (1.05-2.01)) compared to non-lean individuals without NAFLD. However, there was no significant difference in the risk of elevated BP, elevated glucose or atherogenic dyslipidemia between lean NAFLD and non-lean individuals with NAFLD in fully adjusted models.

conclusionLean NAFLD is not metabolically benign. Further cardiovascular risk stratification and appropriate preventive measures should be considered in lean individuals who present with NAFLD.

Indexed as

Cardiometabolic diseaseInflammationLean individualsNon-alcoholic fatty liver diseaseTriglycerides

Identifiers

PMID34327473
PMCPMC8315654
OpenAlexW3093830929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.